Establishment and partial validation of a patient skin self-assessment questionnaire in systemic sclerosis

Rheumatology

Volumn 48, Issue 3, 2009, Pages 309-314

  Nagy, Zoltán ^a,c   Bálint, Zsófia ^b   Farkas, Helka ^b   Radics, Judit ^b   Kumánovics, Gábor ^b   Minier, Tünde ^b   Varjú, Cecília ^b   Czirják, László ^b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

^c Department of Internal Medicine   (Hungary)

Author keywords

Disease activity; Instrument; Modified Rodnan skin score; OMERACT filter; Scleroderma; Self assessment questionnaire; Skin thickness; Systemic sclerosis; Validation

Indexed keywords

ADULT; ARTICLE; BODY WEIGHT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ACTIVITY; FEASIBILITY STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PATIENT SKIN SELF ASSESSMENT QUESTIONNAIRE; PRIORITY JOURNAL; QUESTIONNAIRE; SCLERODERMA; SCORING SYSTEM; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS; TEST RETEST RELIABILITY; VALIDATION STUDY;

ADULT; AGED; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOMETRICS; SCLERODERMA, SYSTEMIC; SELF CARE; SKIN;

EID: 61349086820     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken490     Document Type: Article

References (37)

1. Clements PJ, Lachenbruch PA, Ng SC, Simmons M, Sterz M, Furst DE, Skin score. A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum 1990;33:1256-63.
2. Clements PJ, Hurwitz EL, Wong WK et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: High-dose versus low-dose penicillamine trial. Arthritis Rheum 2000;43:2445-54.
3. DeMarco PJ, Weisman MH, Seibold JR et al. Predictors and outcomes of scleroderma renal crisis: The high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002;46:2983-9.
4. Clements PJ, Wong WK, Hurwitz EL et al. The disability index of the health assessment questionnaire in a predictor and correlate outcome in the high dose versus low dose penicillamine in systemic sclerosis trial. Arthritis Rheum 2001;44:653-61.
5. Clements PJ, Wong WK, Hurwitz EL et al. Correlates of the disability index of the health assessment questionnaire: A measure of functional impairment in systemic sclerosis. Arthritis Rheum 1999;42:2372-80.
6. Sultan N, Pope JE. Clements PJ; Scleroderma Trials Study Group. The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: Results from an analysis of two randomized controlled trials in early diffuse scleroderma. Rheumatology 2004;43:472-8.
7. Brennan P, Silman A, Black C et al. Reliability of skin involvement measures in scleroderma. The UK Scleroderma Study Group. Br J Rheumatol 1992;31:457-60.
8. Pope JE. Variability of skin scores and clinical measurements in scleroderma. J Rheumatol 1995;22:1271-6.
9. Silman A, Harrison M, Brennan P. Is it possible to reduce the observer variability in skin score assessment of scleroderma? J Rheumatol 1995;22:1277-80.
10. Czirják L, Nagy Z, Aringer M, Riemekasten G, Matucci-Cerinic M, Furst DE. EUSTAR. The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis. Ann Rheum Dis 2007;66:966-9.
11. Czirják L, Foeldvari I, Müller-Ladner U. Skin involvement in systemic sclerosis (review). Rheumatology 2008;47(Suppl. 5):v44-5.
12. Steen VD, Medsger TA Jr. The value of the health assessment questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997;40:1984-91.
13. Serednicka K, Smyth AE, Black CM, Denton CP. Using a self-reported functional score to assess disease progression in systemic sclerosis. Rheumatology 2007; 46:107-10.
14. Mouthon L, Rannou F, Bérezné A et al, Development and validation of a scale for mouth handicap in sysemic sclerosis: The mouth handicap in systemic sclerosis scale. Ann Rheum Dis 2007;66:1651-5.
15. Khanna D, Hays RD, Park GS et al. Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument. Arthritis Rheum 2007;57:1280-6.
16. Ostojić P, Damjanov N. The scleroderma assessment questionnaire (SAQ). A new self-assessment questionnaire for evaluation of disease status in patients with systemic sclerosis. Z Rheumatol 2006;65:168-75.
17. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
18. Nagy Z, Czirják L. Increased levels of amino terminal propeptide of type III procollagen are an unfavourable predictor of survival in systemic sclerosis. Clin Exp Rheumatol 2005;23:165-72.
19. Cziják L, Kumánovics G, Varjú C et al. Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 2008;67:59-63.
20. Clements P, Lachenbruch P, Siebold J et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
21. Clements P, Lachenbruch P, Furst D, Paulus H. The course of skin involvement in systemic sclerosis over three years in a trial of chlorambucil versus placebo. Arthritis Rheum 1993;1576-9.
22. Nagy Z, Bálint Zs, Farkas H et al. A szisztémás sclerosisos betegek számára készült módosított HAO kérdoív hazai adaptációja és validálása [The adaptation and validation of scleroderma health assessment questionnaire for the Hungarian systemic sclerosis patients]. Magy Reumatol 2007;48:208-18.
23. Medsger TA Jr, Silman AJ, Steen VD et al, A disease severity scale for systemic sclerosis: Development and testing. J Rheumatol 1999;26:2159-67.
24. Medsger TA Jr. Assessment of damage and activity in systemic sclerosis. Curr Opin Rheumatol 2000;12:545-8.
25. Valentini G, Della Rossa A, Bombardieri S et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001; 60;592-8.
26. Valentini G, Bencivelli W, Bombardieri S et al. European scleroderma study group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis 2003;62:901-3.
27. Hudak PL, Amadio PC, Bombardier C. Development of an upper extremity outcome measure: The DASH (disabilities of the arm, shoulder and hand). The upper extremity collaborative group (UECG). Am J Ind Med 1996;29:602-8.
28. Varjú C, Bálint Zs, Solyom AI et al. Cross-cultural adaptation of the Disabilities of the Arm, Shoulder, and Hand DASH) questionnaire into Hungarian and investigation of' its validity in patients with systemic sclerosis. Clin Exp Rheumatol 2008;26:776-83.
29. Roberts-Thomson AJ, Massy-Westropp N, Smith MD, Ahem MJ, Highton J, Roberts-Thomson PJ. The use of the hand anatomic index to assess deformity and impaired function in systemic sclerosis. Rheumatol Int 2006;26:439-44.
30. Poole JL, Brewer C, Rossie K, Good CC, Conte C, Steen V. Factors related to oral hygiene in persons with scleroderma. Int J Dent Hyg 2005;3:13-7.
31. Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine 2000;25:3186-91.
32. Bellamy N. Clinimetric concepts in outcome assessment: The OMERACT filter. J Rheumatol 1999;26:948-50.
33. Boers M, Brooks P, Strand CV, Tugwell P. The OMERACT filter for outcome measures in rheumatology. J Rheumatol 1998;25:198-9.
34. Altman DG. Practical statistics for medical research. London: Chapman & Hall, 1991;404.
35. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
36. McHomrny CA, Tarlov AR. Individual patient monitoring in clinical practice: Are available health status surveys adequate? Qual Life Res 1995;4:293-307.
37. Gazi H, Pope JE,Qlements P et al. Outcome measurements in scleroderma: Results from a Delphi exercise. J Rheumatol 2007;34:501-9.